Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent anti-atherogenic agents in vivo

被引：9

作者：

Chin, Jungwook ^{[1
]}

Hong, Jun Young ^{[1
]}

Lee, Jaehwan ^{[1
]}

Hwang, Hoosang ^{[1
]}

Ko, Hyunsil ^{[1
]}

Choi, Hyukjae ^{[1
]}

Hahn, Dongyup ^{[1
]}

Ko, Jaeyoung ^{[1
]}

Nam, Sang-Jip ^{[1
]}

Tak, Jungae ^{[1
]}

Ham, Jungyeob ^{[2
]}

Kang, Heonjoong ^{[1
,3
]}

机构：

[1] Seoul Natl Univ, Sch Earth & Environm Sci, Ctr Marine Nat Prod & Drug Discovery, Seoul 151747, South Korea

[2] Korea Inst Sci & Technol, Kangnung 210340, South Korea

[3] SNU, Res Inst Oceanog, Seoul 151741, South Korea

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 24期

关键词：

PPAR delta-selective ligand; Anti-atherogenic agents; Intestinal polyp formation; PPAR-DELTA; MOLECULAR MODIFICATION; ATHEROSCLEROSIS; CHOLESTEROL; SULFIDES; BIOISOSTERISM; BETA/DELTA; MODELS; HEART; MICE;

D O I：

10.1016/j.bmcl.2010.10.103

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the synthesis and in vivo activity of a novel anti-atherogenic agent, isosteric selenium PPAR delta-selective ligand. This ligand did not cause significant body or liver weight changes and did not have obvious adverse effects on intestinal polyp formation. Our overall results clearly demonstrate that PPAR delta is a viable drug candidate for targeting and treating atherosclerosis. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：7239 / 7242

页数：4

共 50 条

[21] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Kolatkar, Nikheel S.
AMERICAN JOURNAL OF MEDICINE, 2013, 126 (03): : E11 - E11
[22] Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B
Fruchart, JC
DIABETES, 2005, 54 (08) : 2460 - 2470
[23] Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
Grommes, C
Landreth, GE
Heneka, MT
LANCET ONCOLOGY, 2004, 5 (07): : 419 - 429
[24] Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Vosper, H
Khoudoli, GA
Graham, TL
Palmer, CNA
PHARMACOLOGY & THERAPEUTICS, 2002, 95 (01) : 47 - 62
[25] Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor α agonists
Faucher, Nicolas
Martres, Paul
Laroze, Alain
Pineau, Olivier
Potvain, Florent
Grillot, Didier
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (02) : 710 - 715
[26] Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo
Xin, XH
Yang, SY
Kowalski, J
Gerritsen, ME
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (13) : 9116 - 9121
[27] From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Dagdelen, Selcuk
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2008, 2 (01) : 24 - 28
[28] The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
Li, Jingjing
Guo, Chuanyong
Wu, Jianye
DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2619 - 2628
[29] Discovery, design, and synthesis of peroxisome proliferator-activated receptor δ agonists
Chin, Jungwook
Lee, Geumwoo
Hwang, Hoosang
Kang, Heonjoong
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[30] Peroxisome proliferator-activated receptor gamma agonists in renal disease
Iglesias, Pedro
Diez, Juan J.
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (05) : 613 - 621

← 1 2 3 4 5 →